2014 Competition Patients Specialization 
pharmaphorum
DECEMBER 14, 2022
When patients experience intense emotion, either positive or negative, they are rendered unconscious. But increased competition is on the horizon. Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Competition starts to heat up.
Pharmaceutical Technology
OCTOBER 5, 2022
Between 2009 and 2014, the time period of Biogen’s alleged misconduct, the standard of care for MS involved the use of Biogen’s immunomodulatory drugs such as Avonex (Interferon beta-1a), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). More recently, Biogen has been facing competition from dimethyl fumarate generics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 17, 2022
The 2019 VPAS , just like its predecessor that was in place from 2014, has at its heart a payback mechanism. The ABPI has a special designation to represent all companies that sell branded medicines in any statutory consultation with the government. Patients, too, are calling for a role this time around.
CloserIQ
OCTOBER 10, 2018
Founded 2014. Kyruus is revolutionizing healthcare with its data-driven system that makes it easier for healthcare system to match patients to appropriate providers. Founded 2014. BondLink is a fintech company specializing in the municipal bond market. Founded 2014. 51-100 employees. 107 million in funding.
Evolve Your Success
MAY 23, 2023
With VR simulations, sales reps can now hone their skills in lifelike scenarios, giving them a competitive edge in the field. There are mountains of data points, clinical studies and validation that’s been done to show that these products and techniques have a significant impact on patient outcomes. Is it relatively brand new?
European Pharmaceutical Review
FEBRUARY 7, 2023
Regulation of clinical trials Eight years following its adoption in 2014, the Clinical Trials Regulation 536/2014 (CTR) entered into application on 31 January 2022. In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR.
Evolve Your Success
FEBRUARY 6, 2024
Mark discusses the role of value analysis in improving their products and services, allowing them to properly address the ever-changing and specific needs of patients. He also talks about partnering with small businesses and how they are leading the competition in this particular space. I left them in 2014 to start our own thing.
Expert insights. Personalized for you.
90 
Let's personalize your content